RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+2.83%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.31B
AUM Growth
+$3.31B
(-16%)
Cap. Flow
-$387M
Cap. Flow
% of AUM
-11.67%
Top 10 Holdings %
Top 10 Hldgs %
35.65%
Holding
121
New
8
Increased
41
Reduced
28
Closed
10
Top Buys
| 1 |
Insmed
INSM
|
$54.2M |
| 2 |
Johnson & Johnson
JNJ
|
$24.8M |
| 3 |
Structure Therapeutics
GPCR
|
$23.1M |
| 4 |
UnitedHealth
UNH
|
$22.9M |
| 5 |
Eli Lilly
LLY
|
$16.5M |
Top Sells
| 1 |
Immunocore
IMCR
|
$66M |
| 2 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$44M |
| 3 |
Penumbra
PEN
|
$43.2M |
| 4 |
Boston Scientific
BSX
|
$32M |
| 5 |
Agios Pharmaceuticals
AGIO
|
$31.1M |
Sector Composition
| 1 | Healthcare | 97.63% |
| 2 | Consumer Staples | 1.87% |
| 3 | Industrials | 0.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
1
DELISTED
Blueprint Medicines
BPMC
| $265M | 7.98% | 2,460,417 -38,031 | -2% | -$4.1M |
|
|
2
UnitedHealth
UNH
$281B
| $140M | 4.22% | 275,000 +45,000 | +20% | +$22.9M |
|
3
Intuitive Surgical
ISRG
$170B
| $133M | 4% | 298,500 | – | – |
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $129M | 3.9% | 940,000 -114,900 | -11% | -$15.8M |
|
|
5
Eli Lilly
LLY
$657B
| $110M | 3.31% | 121,500 +18,250 | +18% | +$16.5M |
|
6
argenx
ARGX
$43.6B
| $98.6M | 2.97% | 229,250 | – | – |
|
7
Acadia Healthcare
ACHC
$2.12B
| $79.5M | 2.39% | 1,177,500 | – | – |
|
8
Ultragenyx Pharmaceutical
RARE
$2.89B
| $79.1M | 2.38% | 1,924,072 +149,134 | +8% | +$6.13M |
|
9
Evolent Health
EVH
$1.12B
| $78M | 2.35% | 4,077,500 +90,000 | +2% | +$1.72M |
|
10
Madrigal Pharmaceuticals
MDGL
$9.76B
| $68.8M | 2.07% | 245,499 -40,432 | -14% | -$11.3M |
|
|
11
Boston Scientific
BSX
$156B
| $63M | 1.89% | 817,500 -415,000 | -34% | -$32M |
|
12
Freshpet
FRPT
$2.72B
| $62.1M | 1.87% | 480,000 -182,500 | -28% | -$23.6M |
|
13
Alnylam Pharmaceuticals
ALNY
$58.5B
| $60.8M | 1.83% | 250,000 +6,000 | +2% | +$1.46M |
|
14
Mirum Pharmaceuticals
MIRM
$3.71B
| $60.6M | 1.82% | 1,772,038 -84,526 | -5% | -$2.89M |
|
15
Merus
MRUS
$4.98B
| $59.2M | 1.78% | 1,001,073 -145,487 | -13% | -$8.61M |
|
16
Idexx Laboratories
IDXX
$51.8B
| $58.2M | 1.75% | 119,500 -59,750 | -33% | -$29.1M |
|
17
Agilon Health
AGL
$530M
| $58.2M | 1.75% | 8,900,000 +65,000 | +0.7% | +$425K |
|
18
DexCom
DXCM
$29.5B
| $56.7M | 1.71% | 500,000 -96,750 | -16% | -$11M |
|
19
Humana
HUM
$36.5B
| $55.1M | 1.66% | 147,408 | – | – |
|
|
20
Insmed
INSM
$28.8B
| $54.2M | 1.63% | +808,356 | New | +$54.2M |
|
21
Rhythm Pharmaceuticals
RYTM
$6.85B
| $52.6M | 1.58% | 1,280,493 -242,400 | -16% | -$9.95M |
|
22
Celldex Therapeutics
CLDX
$1.47B
| $51.8M | 1.56% | 1,398,994 +26,809 | +2% | +$992K |
|
23
Phreesia
PHR
$1.88B
| $51.3M | 1.54% | 2,417,500 +52,500 | +2% | +$1.11M |
|
24
Edwards Lifesciences
EW
$47.8B
| $50.8M | 1.53% | 550,000 -97,300 | -15% | -$8.99M |
|
25
Xenon Pharmaceuticals
XENE
$2.98B
| $49.6M | 1.49% | 1,272,877 +17,300 | +1% | +$675K |
|